← Leaderboards
Kumar Suresh
Progenra, Inc.
$5,007,499
Attributed
$5,007,499
Total exposure
14
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,007,499 · 14
By mechanism
R43$2,971,252 · 12
R44$2,036,247 · 2
Top collaborators
No co-investigators on record.
Most similar at Progenra, Inc.
Same institution · by research overlap
- Michael R Mattern$5,800,503
- David E Sterner$7,582,782
- Benjamin Nicholson$1,181,002
- Seth Goldenberg$265,823
Others in their field
Top investigators on “Ubiquitin-Protein Ligase”
- Rama K Mallampalli · Ohio State University$27,141,834
- Wenyi Wei · Brigham And Women'S Hospital$13,925,530
- Craig M Crews · Yale University$13,006,312
- Alexander J Varshavsky · California Institute Of Technology$12,266,340
- Michaela Ulrike Gack · Harvard Medical School$12,020,722
- Jeffrey Wade Harper · Dana-Farber Cancer Inst$11,601,860
Research focus
Ubiquitin-Protein LigaseMediatingSmall MoleculeCellsPathway InteractionsAnimal ModelUbiquitinIn VitroProductionIn VivoProteinsBaseAgonistMulticatalytic Endopeptidase ComplexHigh Throughput ScreeningEnzyme PathwayLeadInflammatoryAffectCell ModelInflammationFamilyInhibitor/AntagonistDrug Discovery
Grant awards (15)
Ubiquitin pathway modulators as novel antituberculosis drugs$302,421
R43 · FY2025 · AI · contact PI
Ubiquitin pathway modulators for treating pancreatitis$269,622
R43 · FY2024 · DK · contact PI
Parkin activators for cardioprotective therapies$296,932
R43 · FY2022 · HL · contact PI
Development of ITCH-activating IRAK4 degraders as dual-targeting drug candidates for the treatment of rheumatoid arthritis$254,561
R43 · FY2022 · AR · contact PI
Targeted protein stabilization using Protein Rescue Targeting Chimeras (PRESTACs)$297,442
R43 · FY2020 · GM · contact PI
Ubiquitin E3 ligase activators for treatment of psoriasis$224,461
R43 · FY2019 · AR · contact PI
Small molecule Parkin activators to treat Alzheimer's Disease$643,048
R44 · FY2018 · AG · contact PI
Ubiquitin pathway inhibitors for treatment of asthma$636,155
R44 · FY2018 · AI · contact PI
Small-molecule inhibition of mechanisms shared across pathogenic cells in systemic lupus erythematosus$223,362
R43 · FY2018 · AI · contact PI
Ubiquitin pathway inhibitors for treatment of asthma$757,044
R44 · FY2017 · AI · contact PI
Small molecule ubiquitin ligase modulators for immunotherapy of cancer$224,995
R43 · FY2017 · CA · contact PI
Novel ubiquitin protease inhibitor for treating asthma$205,893
R43 · FY2016 · AI · contact PI
Novel E3 ligase inhibitors for treatment of neurodegenerative disease$224,804
R43 · FY2015 · AG · contact PI
Development of selective substrate based inhibitors of ubiquitin isopeptidases$224,379
R43 · FY2014 · GM · contact PI
Ubiquitin pathway inhibitors for treatment of asthma$222,380
R43 · FY2014 · AI · contact PI